Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial. | ClinicLens
Treatment with semaglutide compared with placebo for 24 weeks reduced lean body mass and fat mass in adults with CKD and overweight or obesity. Changes in lean body mass or fat mass during semaglutide treatment did not correlate with changes in creatinine or cystatin C‑eGFR or me
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.